e6 tcr
Vaginal Cancer
National Cancer Institute (NCI)Cell therapyPhase 1/2Dormant
CCC
50/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 89/ 100
Competitive context
10 Active assets in the Vaginal Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fludarabine Christian Hinrichs | Phase 2 | BB |
Cyclophosphamide Christian Hinrichs | Phase 2 | BB |
Octreotide Pamoate Alliance for Clinical Trials in Oncology | Phase 3 | B |
Durvalumab M.D. Anderson Cancer Center | Phase 2 | B |
e7 tcr-t cells Christian Hinrichs | Phase 2 | B |
View all 27 →
Same molecule, other indications
e6 tcr is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →